NEW YORK, Oct. 24, 2018 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE American: ATNM) announced
today that members of the Company's executive team will attend the
BIO-Europe® 24th Annual International Partnering Conference in
Copenhagen, Denmark on
November 5-7, 2018.
BIO-Europe® is the largest life science partnering event
in Europe that is expected to draw
over 4,000 attendees from over 2,000 companies.
Actinium is developing Antibody Radio-Conjugates (ARCs) that
deliver radioisotopes in a targeted manner to cells expressing CD45
and CD33 for multiple hematologic indications. Actinium is the only
company with multi-disease, multi-target pipeline focused on
improving access and outcomes to cellular therapies including bone
marrow transplant and CAR-T through targeted conditioning.
Actinium's lead targeted conditioning product candidate, Iomab-B,
is currently being studied in a pivotal Phase 3 trial. Actinium's
best-in-class CD33 program is being studied in multiple trials as
both a targeted conditioning agent and therapeutic for patients
with Acute Myeloid Leukemia, Myelodysplastic Syndrome and Multiple
Myeloma. Underpinning Actinium's clinical programs is its Antibody
Warhead Enabling technology that has been studied in both
hematologic and solid tumors, which could be utilized to create
ARCs for numerous targets and indications.
Sandesh Seth, Actinium's Chairman
and Chief Executive Officer said, "We are particularly excited for
this year's BIO-Europe Partnering Conference for a multitude of
reasons. Given the progress and expansion of our targeted
conditioning pipeline combined with the strong interest for
radiopharmaceutical therapies of late, we look forward to what we
expect to be a productive and valuable conference. First and
foremost, we will be able to highlight extensive clinical data from
our highly differentiated CD45 and CD33 ARCs for targeted
conditioning and therapeutic indications, which have been studied
in over 600 patients across 14 clinical trials. We will also
showcase our recently unveiled Iomab-ACT program that we intend to
make a universally available next generation lymphodepletion
solution prior to CAR-T therapy. Additionally, we will present our
AWE technology platform to potential collaborators and partners
just as we have with our established AWE collaborator Astellas
Pharma, Inc."
Conference attendees may schedule a meeting with Actinium's
management through the conference's partnering system
https://ebdgroup.knect365.com/bioeurope/login or by contacting
Steve O'Loughlin, Actinium's
Principal Financial Officer, soloughlin@actiniumpharma.com.
About BIO-Europe
The 24th annual BIO-Europe is Europe's largest partnering conference serving
the global biotechnology industry. Delegates from all parts of the
biotechnology value chain come to BIO-Europe to quickly identify,
engage and enter strategic relationships that drive their
businesses successfully forward. Investment and collaboration
opportunities developed in prior BIO-Europe conferences have
produced many highly successful business partnerships. BIO-Europe
is organized by EBD Group, the leading partnering firm for the
global biotechnology industry, in alliance with the Biotechnology
Industry Organization (BIO)
About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is focused on improving patient
access and outcomes to cellular therapies such as bone marrow
transplant (BMT) and CAR-T with its proprietary, chemotherapy free
or sparing, targeted conditioning technology. Actinium is the only
company with a multi-disease, multi-target, drug development
pipeline focused on targeted conditioning. Its targeted
conditioning technology is enabled by ARC's or Antibody
Radio-Conjugates that combine the targeting ability of monoclonal
antibodies with the cell killing ability of radioisotopes.
Actinium's pipeline of clinical-stage targeted conditioning ARCs
target the antigens CD45 and CD33 for patients with a broad range
of hematologic malignancies including Acute Myeloid Leukemia (AML),
Myelodysplastic Syndrome (MDS) and Multiple Myeloma (MM), Acute
Lymphoblastic Leukemia (ALL), Hodgkin's Lymphoma and Non-Hodgkin's
Lymphoma. Actinium's Iomab-ACT program is designed to be a
universal lymphodepletion technology intended to eliminate the need
for chemotherapy-based conditioning prior to CAR-T or other
adoptive cellular therapies.
Iomab-B, Actinium's lead targeted conditioning product
candidate, is currently enrolling patients in the pivotal Phase 3
SIERRA trial in patients age 55 or older, with active, relapsed or
refractory AML. Iodine-131-apamistamab (Iomab-B), combines the
anti-CD45 monoclonal antibody labeled with iodine-131 for
myeloablation prior to a bone marrow transplant. CD45 is expressed
on leukemia, lymphoma and normal immune cells. Iomab-B has been
studied in over 500 patients in 10 clinical trials in numerous
hematologic diseases. Actinium's Iomab-ACT program is an expansion
of its CD45 program that is intended to be a universal,
chemotherapy-free solution for targeted lymphodepletion prior to
CAR-T. Through targeted lymphodepletion, the Iomab-ACT program is
expected to improve CAR-T cell expansion, reduce CAR-T related
toxicities and expand patient access to CAR-T treatment and
potentially other adoptive cell therapies. Due to its lower payload
dose, lymphodepletion with the Iomab-ACT program can be
accomplished through a single outpatient infusion. Actinium intends
to advance its Iomab-ACT program with CAR-T focused collaborators
from academia and industry.
Actinium's pipeline also includes a potentially best-in-class
CD33 program with its ARC comprised of the anti-CD33 antibody
lintuzumab labeled with the alpha-particle emitter actinium-225.
Its CD33 program is currently being studied in multiple Phase 2 and
Phase 1 clinical trials for targeting conditioning and as a
therapeutic in multiple diseases and indications including AML, MDS
and MM. Actinium applies its CD33 program at high doses to target
CD33+ cells of the myeloid lineage in combination with reduced
intensity conditioning (RIC), which together are intended to result
in myeloablative outcomes with a more benign and well tolerated
profile than high intensity chemotherapy myeloablation. Actinium is
focused on applying its CD33 program at low doses in combination
with other therapeutic modalities including chemotherapy, targeted
agents and immunotherapies.
Actinium is also developing its proprietary AWE or Antibody
Warhead Enabling technology platform which utilizes radioisotopes
including iodine-131 and the highly differentiated actinium-225
coupled with antibodies to target a variety of antigens that are
expressed in hematological and solid tumor cancers. The AWE
technology enables Actinium's internal pipeline and with the
radioisotope Actinium-225 is being utilized in a collaborative
research partnership with Astellas Pharma, Inc. Actinium's clinical
programs and AWE technology platform are covered by a portfolio of
77 patents covering composition of matter, formulations, methods of
use and also methods of manufacturing the radioisotope Actinium-225
in a cyclotron.
More information is available at www.actiniumpharma.com and our
Twitter feed @ActiniumPharma, www.twitter.com/actiniumpharma.
Forward-Looking Statements for Actinium Pharmaceuticals,
Inc.
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Actinium Pharmaceuticals, Inc.
Steve O'Loughlin
Principal Financial Officer
soloughlin@actiniumpharma.com
Investor Relations
Rx Communications Group
Paula Schwartz
917-322-2216
pschwartz@rxir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-participation-at-bio-europe-24th-annual-international-partnering-conference-300736713.html
SOURCE Actinium Pharmaceuticals, Inc.